Non-alcoholic fatty liver disease (NAFLD): assessment and management

Recommendation ID: NG49/5
Question: Pharmacological therapy for advanced liver fibrosis in children and young people:- What is the clinical and cost effectiveness of pharmacological therapy in children and young people with advanced liver fibrosis?
Any explanatory notes (if applicable): Why this is important:- Observational studies reported that up to 10% of children and young people diagnosed with NAFLD progress to advanced liver fibrosis and are at risk of developing advanced stages of liver disease. Pharmacological treatment (for example, pioglitazone or vitamin E) could prevent progression to advanced liver fibrosis or end-stage liver disease, as has been reported in a number of high quality studies in adults with confirmed NAFLD. There are insufficient data on the efficacy of similar pharmacological treatment in children and young people with NAFLD to make clear treatment recommendations.

Source guidance details

Comes from guidance: Non-alcoholic fatty liver disease (NAFLD): assessment and management
Number: NG49
Date issued: July 2016

Is this a recommendation for the use of a technology only in the context of research?	No
Is it a recommendation that suggests collection of data or the establishment of a register?	No
Last Reviewed	31/07/2016